{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:07:28Z","timestamp":1791976048563,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40262-025-01475-7","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:57:39Z","timestamp":1739822259000},"page":"533-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes"],"prefix":"10.1007","volume":"64","clinical-trial-number":[{"clinical-trial-number":"nct03745885","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04314622","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04994288","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04998032","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7717-6010","authenticated-orcid":false,"given":"Yan-Ru","family":"Lou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5560-1102","authenticated-orcid":false,"given":"Yu-Long","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"issue":"4","key":"1475_CR1","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740\u201356.","journal-title":"Cell Metab"},{"key":"1475_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46: 101102.","journal-title":"Mol Metab"},{"issue":"2","key":"1475_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.regpep.2004.06.001","volume":"128","author":"CH McIntosh","year":"2005","unstructured":"McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept. 2005;128(2):159\u201365.","journal-title":"Regul Pept"},{"issue":"10454","key":"1475_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","volume":"404","author":"J Deanfield","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773\u201386.","journal-title":"Lancet"},{"issue":"19","key":"1475_CR5","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"14","key":"1475_CR6","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"2","key":"1475_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2337\/dci19-0066","volume":"43","author":"JB Buse","year":"2020","unstructured":"Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487\u201393.","journal-title":"Diabetes Care"},{"issue":"6","key":"1475_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/HCO.0000000000001084","volume":"38","author":"RM Goldenberg","year":"2023","unstructured":"Goldenberg RM, Teoh H, Verma S. Glucagon-like peptide-1\/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data. Curr Opin Cardiol. 2023;38(6):539\u201345.","journal-title":"Curr Opin Cardiol"},{"key":"1475_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3\u201314.","journal-title":"Mol Metab."},{"issue":"9","key":"1475_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","volume":"10","author":"N Inagaki","year":"2022","unstructured":"Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):623\u201333.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1475_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012734","volume":"5","author":"Q Wang","year":"2010","unstructured":"Wang Q, Chen K, Liu R, Zhao F, Gupta S, Zhang N, et al. Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS\u00a0One. 2010;5(9): e12734.","journal-title":"PLoS\u00a0One"},{"issue":"2","key":"1475_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1530\/JOE-20-0255","volume":"248","author":"Q Cui","year":"2021","unstructured":"Cui Q, Liao Y, Jiang Y, Huang X, Tao W, Zhou Q, et al. Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys. J Endocrinol. 2021;248(2):145\u201354.","journal-title":"J Endocrinol"},{"key":"1475_CR13","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3389\/fphys.2019.00930","volume":"10","author":"L Ren","year":"2019","unstructured":"Ren L, Cui Q, Liu W, Wang L, Liao Y, Feng Y, et al. Novel GLP-1 analog supaglutide stimulates insulin secretion in mouse and human islet beta-cells and improves glucose homeostasis in diabetic mice. Front Physiol. 2019;10:930.","journal-title":"Front Physiol"},{"key":"1475_CR14","unstructured":"Specific instructions for the use of organ dysfunction templates. https:\/\/ctep.cancer.gov\/protocoldevelopment\/docs\/hepatic_dysfunction_template_v4.docx."},{"issue":"12","key":"1475_CR15","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1056\/NEJMoa0908292","volume":"362","author":"W Yang","year":"2010","unstructured":"Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090\u2013101.","journal-title":"N Engl J Med"},{"issue":"2","key":"1475_CR16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/dom.13082","volume":"20","author":"Y Seino","year":"2018","unstructured":"Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):378\u201388.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1475_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/jech-2020-216158","volume":"76","author":"T Sengoku","year":"2022","unstructured":"Sengoku T, Ishizaki T, Goto Y, Iwao T, Ohtera S, Sakai M, et al. Prevalence of type 2 diabetes by age, sex and geographical area among two million public assistance recipients in Japan: a cross-sectional study using a nationally representative claims database. J Epidemiol Community Health. 2022;76(4):391\u20137.","journal-title":"J Epidemiol Community Health"},{"issue":"5","key":"1475_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40262-015-0338-3","volume":"55","author":"JS Geiser","year":"2016","unstructured":"Geiser JS, Heathman MA, Cui X, Martin J, Loghin C, Chien JY, et al. Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials. Clin Pharmacokinet. 2016;55(5):625\u201334.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1475_CR19","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1111\/dom.13358","volume":"20","author":"KCC Petri","year":"2018","unstructured":"Petri KCC, Ingwersen SH, Flint A, Zacho J, Overgaard RV. Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes. Diabetes Obes Metab. 2018;20(9):2238\u201345.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1475_CR20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/psp4.13099","volume":"13","author":"K Schneck","year":"2024","unstructured":"Schneck K, Urva S. Population pharmacokinetics of the GIP\/GLP receptor agonist tirzepatide. CPT Pharmacomet Syst Pharmacol. 2024;13(3):494\u2013503.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"6","key":"1475_CR21","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40262-021-01094-y","volume":"61","author":"Y Guan","year":"2022","unstructured":"Guan Y, Ly N, Li J, Arends RH. Population pharmacokinetics of cotadutide in subjects with type 2 diabetes. Clin Pharmacokinet. 2022;61(6):833\u201345.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1475_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s13300-019-0581-y","volume":"10","author":"RV Overgaard","year":"2019","unstructured":"Overgaard RV, Delff PH, Petri KCC, Anderson TW, Flint A, Ingwersen SH. Population pharmacokinetics of semaglutide for type 2 diabetes. Diabetes Ther. 2019;10(2):649\u201362.","journal-title":"Diabetes Ther."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01475-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01475-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01475-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:24:53Z","timestamp":1745940293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01475-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1475"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01475-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"31 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Shanghai Innogen Pharmaceutical Technology Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Y.-R.L., Y.-L.X., and Q.W. are employees of Shanghai Innogen Pharmaceutical Technology Co., Ltd. Y.X. and C.D. are employees of Linking Truth Technology Co., Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Y.-R.L. drafted the manuscript. Y.-L.X., Y.X., C.D., and Q.W. reviewed and edited the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"All studies included in this analysis were approved by the relevant ethics committees and conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation guidelines for Good Clinical Practice (ICH-GCP).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Data will be made available upon reasonable request, subject to the protection of research participants\u2019 privacy.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}}]}}